Gyre Therapeutics Inc (GYRE)

$7.57 +0.27 (3.63%)
Market Cap 703.71M
Revenue (ttm) 105.76M
Net Income (ttm) 12.09M
EPS (ttm) N/A
PE Ratio 87.13
Forward PE 25.82
Profit Margin 11.43%
Debt to Equity Ratio 0.00
Volume 101,800
Avg Vol 76,250
Day's Range N/A - N/A
Shares Out 96.33M
Stochastic %K 62%
Beta 1.99
Analysts Strong Sell
Price Target $18.00

Company Profile

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 619 949 3681
Address:
12770 High Bluff Drive, Suite 150, San Diego, United States
Channelchek
Channelchek Jan. 6 at 1:30 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Hydronidone NDA Planned For 1H26, Meeting Expected Milestone Positive Guidance Received From CDE. Gyre announced that its majority-owned subsidiary in China, Gyre Pharmaceuticals Ltd, has completed pre-NDA discussions with the Chinese Center for Drug Evaluation (CDE). Read the full report here: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-hydronidone-nda-planned-for-1h26-meeting-expected-milestone
0 · Reply
topstockalerts
topstockalerts Jan. 5 at 6:47 PM
Gyre Therapeutics reported a successful pre–New Drug Application meeting with Chinese regulators for its liver fibrosis treatment, Hydronidone. China’s Center for Drug Evaluation agreed that existing Phase 3 clinical data support a conditional approval filing, with the drug also eligible for priority review pending formal acceptance. Gyre plans to submit an NDA in the first half of 2026 for Hydronidone, which targets liver fibrosis associated with chronic hepatitis B, including early cirrhosis. A confirmatory clinical trial will be conducted to support full approval in China. The regulatory update follows positive Phase 3 results announced in May 2025, showing fibrosis regression at Week 52 in 52.85% of treated patients versus 29.84% with placebo. Hydronidone previously received Breakthrough Therapy Designation from China’s regulator, highlighting its potential to address a major unmet need where no approved antifibrotic therapies currently exist. $GYRE
0 · Reply
notreload_ai
notreload_ai Jan. 5 at 5:38 PM
$GYRE stock jumps after Chinese regulators agree to conditional approval pathway for Hydronidone, a first-in-class liver fibrosis treatment. https://notreload.xyz/gyre-therapeutics-gains-on-china-drug-approval-pathway/
0 · Reply
PersonaPulse
PersonaPulse Dec. 27 at 2:35 PM
$GYRE Short‑term swings mask the deeper question: can discipline hold; cost controls have to translate into healthier margins — any stumble could quickly widen valuation discounts. Until validation appears, volatility remains the default.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 5 at 2:54 PM
$GYRE Share Price: $7.80 Contract Selected: Apr 17, 2026 $10 Calls Buy Zone: $0.92 – $1.13 Target Zone: $1.56 – $1.91 Potential Upside: 61% ROI Time to Expiration: 132 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Channelchek
Channelchek Nov. 10 at 4:32 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Gyre Reports 3Q25 With Several Clinical Trial Updates Quarter Sales Were Driven By Etuary. Gyre reported Net Income of $5.9 million or $0.04 per basic share. Revenue of $30.6 million showed year-over-year growth of 20.0%. This was driven by strength in Etuary with sales of $27.7 million. Sales of Etorel and Contiva sales were of $1.5 million and $1.2 million respectively. At the end of 3Q25 on September 30, the company had $80.3 in cash, equivalents, and securities. Read more: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-gyre-reports-3q25-with-several-clinical-trial-updates
0 · Reply
Channelchek
Channelchek Nov. 3 at 2:42 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Looking Forward To Phase 3 Data Presentation This Week Phase 3 Data To Be Presented At A Medical Meeting. Presentation of data from the Hydronidone Phase 3 trial is scheduled for Friday, November 7,2025 at the The Liver Meeting, the annual conference of the American Association for the Study of Liver Disease (AASLD). This presentation is expected to give detailed clinical data on the actions Hydronidone in liver fibrosis associated with chronic hepatitis B infection. We see this indication as proof of concept as well as a revenue opportunity. Read more: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-looking-forward-to-phase-3-data-presentation-this-week
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 15 at 11:18 AM
$GYRE Gyre Therapeutics Has Completed Patient Enrollment In The 52-week Phase 3 Trial In China Of Pirfenidone Capsules, For Pneumoconiosis
0 · Reply
MilsLearning
MilsLearning Oct. 13 at 8:04 AM
$GYRE "L"ets "F" "S"horts 🩳🔥🩳🔥🩳🖕🩳🖕🩳🖕🔜🕖✅ Ever get bullied??? Trading stocks?? Me too!!! Get the bullies out of the schools 🏫 The IPO Foreign Meme movement ***LFS***
0 · Reply
Godwins26
Godwins26 Oct. 10 at 10:10 PM
7th Watchlist for the week 😊 $EPWK $YGMZ $DVLT $GYRE $ORBS
1 · Reply
Latest News on GYRE
Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

Jan 5, 2026, 7:00 AM EST - 3 days ago

Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

Nov 7, 2025, 6:00 AM EST - 2 months ago

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

Oct 15, 2025, 7:00 AM EDT - 3 months ago

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

Oct 14, 2025, 7:00 AM EDT - 3 months ago

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 4:05 PM EDT - 4 months ago

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

Aug 26, 2025, 2:53 PM EDT - 4 months ago

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

Aug 22, 2025, 7:00 AM EDT - 4 months ago

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

Aug 11, 2025, 4:01 PM EDT - 5 months ago

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

Jun 10, 2025, 7:00 AM EDT - 7 months ago

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

May 29, 2025, 4:01 PM EDT - 8 months ago

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

May 22, 2025, 8:57 PM EDT - 8 months ago

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

May 22, 2025, 4:02 PM EDT - 8 months ago

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

May 22, 2025, 4:01 PM EDT - 8 months ago

Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025, 6:00 AM EDT - 8 months ago

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Mar 31, 2025, 7:00 AM EDT - 10 months ago

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Mar 27, 2025, 7:00 AM EDT - 10 months ago

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 17, 2025, 4:15 PM EDT - 10 months ago

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Nov 13, 2024, 6:00 AM EST - 1 year ago

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Oct 1, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Aug 13, 2024, 6:00 AM EDT - 1 year ago

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Aug 9, 2024, 7:00 AM EDT - 1 year ago

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Jun 18, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

May 30, 2024, 4:05 PM EDT - 1 year ago

Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

May 28, 2024, 4:05 PM EDT - 1 year ago

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:10 PM EDT - 1 year ago

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 26, 2024, 6:00 AM EDT - 1 year ago

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

Dec 15, 2023, 9:04 AM EST - 2 years ago

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting

Nov 13, 2023, 7:00 AM EST - 2 years ago

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting

Channelchek
Channelchek Jan. 6 at 1:30 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Hydronidone NDA Planned For 1H26, Meeting Expected Milestone Positive Guidance Received From CDE. Gyre announced that its majority-owned subsidiary in China, Gyre Pharmaceuticals Ltd, has completed pre-NDA discussions with the Chinese Center for Drug Evaluation (CDE). Read the full report here: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-hydronidone-nda-planned-for-1h26-meeting-expected-milestone
0 · Reply
topstockalerts
topstockalerts Jan. 5 at 6:47 PM
Gyre Therapeutics reported a successful pre–New Drug Application meeting with Chinese regulators for its liver fibrosis treatment, Hydronidone. China’s Center for Drug Evaluation agreed that existing Phase 3 clinical data support a conditional approval filing, with the drug also eligible for priority review pending formal acceptance. Gyre plans to submit an NDA in the first half of 2026 for Hydronidone, which targets liver fibrosis associated with chronic hepatitis B, including early cirrhosis. A confirmatory clinical trial will be conducted to support full approval in China. The regulatory update follows positive Phase 3 results announced in May 2025, showing fibrosis regression at Week 52 in 52.85% of treated patients versus 29.84% with placebo. Hydronidone previously received Breakthrough Therapy Designation from China’s regulator, highlighting its potential to address a major unmet need where no approved antifibrotic therapies currently exist. $GYRE
0 · Reply
notreload_ai
notreload_ai Jan. 5 at 5:38 PM
$GYRE stock jumps after Chinese regulators agree to conditional approval pathway for Hydronidone, a first-in-class liver fibrosis treatment. https://notreload.xyz/gyre-therapeutics-gains-on-china-drug-approval-pathway/
0 · Reply
PersonaPulse
PersonaPulse Dec. 27 at 2:35 PM
$GYRE Short‑term swings mask the deeper question: can discipline hold; cost controls have to translate into healthier margins — any stumble could quickly widen valuation discounts. Until validation appears, volatility remains the default.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 5 at 2:54 PM
$GYRE Share Price: $7.80 Contract Selected: Apr 17, 2026 $10 Calls Buy Zone: $0.92 – $1.13 Target Zone: $1.56 – $1.91 Potential Upside: 61% ROI Time to Expiration: 132 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Channelchek
Channelchek Nov. 10 at 4:32 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Gyre Reports 3Q25 With Several Clinical Trial Updates Quarter Sales Were Driven By Etuary. Gyre reported Net Income of $5.9 million or $0.04 per basic share. Revenue of $30.6 million showed year-over-year growth of 20.0%. This was driven by strength in Etuary with sales of $27.7 million. Sales of Etorel and Contiva sales were of $1.5 million and $1.2 million respectively. At the end of 3Q25 on September 30, the company had $80.3 in cash, equivalents, and securities. Read more: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-gyre-reports-3q25-with-several-clinical-trial-updates
0 · Reply
Channelchek
Channelchek Nov. 3 at 2:42 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Looking Forward To Phase 3 Data Presentation This Week Phase 3 Data To Be Presented At A Medical Meeting. Presentation of data from the Hydronidone Phase 3 trial is scheduled for Friday, November 7,2025 at the The Liver Meeting, the annual conference of the American Association for the Study of Liver Disease (AASLD). This presentation is expected to give detailed clinical data on the actions Hydronidone in liver fibrosis associated with chronic hepatitis B infection. We see this indication as proof of concept as well as a revenue opportunity. Read more: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-looking-forward-to-phase-3-data-presentation-this-week
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 15 at 11:18 AM
$GYRE Gyre Therapeutics Has Completed Patient Enrollment In The 52-week Phase 3 Trial In China Of Pirfenidone Capsules, For Pneumoconiosis
0 · Reply
MilsLearning
MilsLearning Oct. 13 at 8:04 AM
$GYRE "L"ets "F" "S"horts 🩳🔥🩳🔥🩳🖕🩳🖕🩳🖕🔜🕖✅ Ever get bullied??? Trading stocks?? Me too!!! Get the bullies out of the schools 🏫 The IPO Foreign Meme movement ***LFS***
0 · Reply
Godwins26
Godwins26 Oct. 10 at 10:10 PM
7th Watchlist for the week 😊 $EPWK $YGMZ $DVLT $GYRE $ORBS
1 · Reply
notreload_ai
notreload_ai Oct. 10 at 1:27 PM
Jefferies began coverage of $GYRE with a Buy rating and a $16 price target. The company is growing in China, aiding its pipeline progress. The lead asset Hydronidone 's Phase 3 study in chronic hepatitis B may lead to a first-in-class launch in China in 2026.
0 · Reply
JarvisFlow
JarvisFlow Oct. 10 at 11:28 AM
Jefferies updates rating for Gyre Therapeutics ( $GYRE ) to Buy, target set at 16.
0 · Reply
JohnnyArtis200
JohnnyArtis200 Sep. 22 at 6:22 AM
$GYRE Marine services cyclicality. Testing support level. Volume decline concerning. Sector headwinds.
0 · Reply
NetworkNewsWire
NetworkNewsWire Sep. 9 at 3:57 PM
BioMedNewsBreaks — $GYRE Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone https://ibn.fm/9wCTA
0 · Reply
Channelchek
Channelchek Sep. 9 at 1:50 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Positioned To End YE2025 With Strong Products and Pipeline Development Gyre Has Made Strong YTD Progress. Gyre has made significant progress during the first three quarters of FY2025 that we believe positions the company for a strong year-end. These developments include continued sales growth from two products introduced in 1H25, an application for Hydronidone approval in China, and the start of a Phase 2 clinical trial for Hydronidone in the US. The company also announced the appointment of Dr. Han Ying as the new CEO, a member of the Board of Directors since January 2025. Read more: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-positioned-to-end-ye2025-with-strong-products-and-pipeline-development
0 · Reply
miop
miop Aug. 31 at 2:57 AM
HuiopkloiuytrewQA $GYRE
0 · Reply
MalwareOfMarkets
MalwareOfMarkets Aug. 29 at 4:12 PM
$GYRE god damm waineright buy rating dropping now
0 · Reply
JarvisFlow
JarvisFlow Aug. 26 at 11:30 AM
HC Wainwright & Co. updates rating for Gyre Therapeutics ( $GYRE ) to Buy, target set at 18.
0 · Reply
MalwareOfMarkets
MalwareOfMarkets Aug. 13 at 10:45 PM
$GYRE and 8.27
0 · Reply
MalwareOfMarkets
MalwareOfMarkets Aug. 7 at 3:35 PM
$GYRE now 7.27
0 · Reply